Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD40 activation: lessons for HIV immunotherapy from malignancies?

Rifca Le Dieu1, John Gribben

  • 1CRUK Medical Oncology Unit, St Bartholomew's and The London School of Medicine, Queen Mary, University of London, UK.

Journal of HIV Therapy
|January 3, 2006
PubMed
Summary

Human immunodeficiency virus (HIV) impairs immune cells, including T-cells and antigen-presenting cells (APCs). Restoring CD4 T-cell help via CD154 (CD40 ligand) may enhance anti-HIV responses and tumor surveillance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lamin B1 safeguards the B cell genome and shapes lymphoma outcome.

HemaSphere·2026
Same author

Exploiting PP2A dependent and independent effects of forskolin for therapeutic targeting of KMT2A (MLL)-rearranged acute leukaemia.

British journal of pharmacology·2025
Same author

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

The New England journal of medicine·2025
Same author

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.

Leukemia·2025
Same author

Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk.

Case reports in hematology·2024
Same author

Influence of donor-recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation.

HemaSphere·2024

Area of Science:

  • Immunology
  • Virology
  • Oncology

Background:

  • HIV infection causes immune defects in T-cells and antigen-presenting cells (APCs), leading to increased infections and tumors.
  • A key defect in HIV is the impaired ability of CD4 T-cells to provide CD154 (CD40 ligand)-mediated help, crucial for APC function.

Purpose of the Study:

  • To explore the potential of CD40 activation to enhance immune responses in HIV.
  • To investigate if CD40 activation can improve anti-HIV viral clearance and tumor surveillance.

Main Methods:

  • The study discusses the known roles of CD40 activation in lymphomas and its potential application in HIV.
  • It focuses on the immunological mechanisms involving CD4 T-cells, CD154, and APCs.

Main Results:

Related Experiment Videos

  • CD40 activation in lymphomas increases APC activity and anti-tumor immune responses.
  • The failure of CD4 T-cells to provide CD154 help is identified as a major defect in HIV.

Conclusions:

  • Activating CD40 may be a therapeutic strategy to boost anti-HIV immune responses.
  • Enhancing CD40 signaling could improve immune surveillance against tumors in HIV-infected individuals.